Ірландія - англійська - HPRA (Health Products Regulatory Authority)

santen oy - tafluprost; timolol maleate - eye drops, solution - 15/5 microgram(s)/millilitre - timolol, combinations

Мальта - англійська - Medicines Authority

santen oy niittyhaankatu 20, 33720 tampere, finland - tafluprost, timolol maleate - eye drops, solution - tafluprost 15 µg/ml timolol maleate 5 mg/ml - ophthalmologicals

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

santen pharma malaysia sdn. bhd. - tafluprost; timolol maleate -

Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

santen oy - timolol maleate 6,84 mg/ml - eq. timolol 5 mg/ml; tafluprost 15 µg/ml - eye drops, solution - 15 µg/ml - 5 mg/ml - timolol maleate 6.84 mg/ml; tafluprost 15 µg/ml - timolol, combinations

США - англійська - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg - timolol maleate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. timolol is indicated for the prophylaxis of migraine headache. timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; hypersensitivity to this product.

США - англійська - NLM (National Library of Medicine)

avera mckennan hospital - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg - timolol maleate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. timolol is indicated for the prophylaxis of migraine headache. timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; hypersensitivity to this product.

США - англійська - NLM (National Library of Medicine)

akorn - timolol (unii: 817w3c6175) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml - timolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol is contraindicated in patients with overt heart failure, cardiogenic shock, sinus bradycardia, second- or third-degree atrioventricular block, bronchial asthma or history of bronchial asthma, or severe chronic obstructive pulmonary disease, or hypersensitivity to any component of this product.

США - англійська - NLM (National Library of Medicine)

akorn - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg in 1 ml - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timolol maleate ophthalmic solution, usp 0.5% (ti-moe-lahl mal-ee-ate) read this instructions for use that comes with timolol maleate ophthalmic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol maleate ophthalmic solution: how should i use timolol maleate ophthalmic solution? step 1. wash your

США - англійська - NLM (National Library of Medicine)

sandoz inc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 5 mg in 1 ml - timolol gfs 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol gfs is contraindicated in patients with: • bronchial asthma • history of bronchial asthma • severe chronic obstructive pulmonary disease • sinus bradycardia • second or third degree atrioventricular block • overt cardiac failure • cardiogenic shock • hypersensitivity to any component of this product. teratogenic effects pregnancy category c: teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in

США - англійська - NLM (National Library of Medicine)

pacific pharma, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol anhydrous 2.5 mg in 1 ml - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.